Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Adults - 18 - 64
  • South Carolina
  • North Charleston


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.
    NCT04177108
    Condition:   Triple-Negative Breast Cancer
    Interventions:   Drug: Atezolizumab;   Drug: Ipatasertib;   Drug: Paclitaxel;   Drug: Placebo for Atezolizumab;   Drug: Placebo for Ipatasertib
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee
    NCT04129944
    Condition:   Osteoarthritis, Knee
    Interventions:   Drug: UBX0101;   Other: Placebo
    Sponsor:   Unity Biotechnology, Inc.
    Recruiting
  • Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma
    NCT04046939
    Conditions:   Eosinophilic Asthma;   Asthma
    Interventions:   Drug: low-dose dexpramipexole;   Drug: mid-dose dexpramipexole;   Drug: high-dose dexpramipexole;   Drug: placebo oral tablet
    Sponsor:   Knopp Biosciences
    Recruiting
  • A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
    NCT04003389
    Condition:   Hot Flashes
    Interventions:   Drug: fezolinetant;   Drug: placebo
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting
  • A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause
    NCT04003155
    Condition:   Hot Flashes
    Interventions:   Drug: fezolinetant;   Drug: placebo
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting
  • Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
    NCT03902080
    Condition:   Overactive Bladder
    Interventions:   Drug: Vibegron;   Drug: Placebo
    Sponsor:   Urovant Sciences GmbH
    Recruiting
  • A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
    NCT03843125
    Condition:   Systemic Lupus Erythematosus
    Intervention:   Drug: Baricitinib
    Sponsors:   Eli Lilly and Company;   Incyte Corporation
    Recruiting
  • Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Sinusitis With or Without the Presence of Nasal Polyps
    NCT03781804
    Condition:   Chronic Sinusitis
    Intervention:   Drug: OPN-375
    Sponsor:   Optinose US Inc.
    Recruiting
  • Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
    NCT03738423
    Condition:   Atopic Dermatitis
    Interventions:   Drug: REGN3500;   Drug: REGN3500-Matching Placebo
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi
    Recruiting
  • Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
    NCT03712345
    Conditions:   Granulomatosis With Polyangiitis (GPA);   Microscopic Polyangiitis (MPA)
    Interventions:   Drug: IFX-1;   Drug: Placebo
    Sponsors:   InflaRx GmbH;   Iqvia Pty Ltd
    Recruiting
  • Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
    NCT03662204
    Conditions:   Breast Cancer;   Lung Cancer;   Colorectal Cancer;   Prostate Cancer;   Bladder Cancer;   Uterine Cancer;   Kidney Cancer;   Renal Pelvis Cancer;   Pancreatic Cancer;   Liver Cancer;   Stomach Cancer;   Ovarian Cancer;   Esophageal Cancer
    Intervention:   Other: Blood Sample Collection
    Sponsor:   Exact Sciences Corporation
    Recruiting
  • A Study of Baricitinib in Participants With Systemic Lupus Erythematosus
    NCT03616964
    Condition:   Systemic Lupus Erythematosus
    Interventions:   Drug: Baricitinib;   Drug: Placebo
    Sponsors:   Eli Lilly and Company;   Incyte Corporation
    Recruiting
  • Etokimab in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
    NCT03614923
    Condition:   Chronic Rhinosinusitis
    Interventions:   Biological: Etokimab;   Biological: Placebo
    Sponsor:   AnaptysBio, Inc.
    Recruiting
  • SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)
    NCT03607838
    Condition:   Lumbar Disc Herniation
    Interventions:   Drug: SI-6603;   Drug: Sham injection
    Sponsor:   Seikagaku Corporation
    Recruiting
  • Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND
    NCT03587805
    Condition:   Atopic Dermatitis
    Intervention:   Drug: Tralokinumab
    Sponsor:   LEO Pharma
    Recruiting
  • Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors
    NCT03561883
    Condition:   Gastroesophageal Reflux Disease (GERD)
    Interventions:   Drug: IW-3718;   Drug: placebo
    Sponsor:   Ironwood Pharmaceuticals, Inc.
    Recruiting
  • Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
    NCT02403323
    Condition:   Crohn Disease
    Intervention:   Drug: Etrolizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease
    NCT02394028
    Condition:   Crohn Disease
    Interventions:   Drug: Etrolizumab;   Drug: Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
    NCT02118584
    Condition:   Ulcerative Colitis
    Intervention:   Drug: Etrolizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
    NCT01920061
    Condition:   Neoplasm
    Interventions:   Drug: PF-05212384 (gedatolisib);   Drug: Docetaxel;   Drug: Cisplatin;   Drug: Dacomitinib
    Sponsor:   Pfizer
    Recruiting
  • Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
    NCT03985943
    Condition:   Moderate-to-Severe Atopic Dermatitis
    Interventions:   Drug: Placebo;   Drug: Nemolizumab
    Sponsor:   Galderma R&D
    Recruiting
  • A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
    NCT03580356
    Condition:   Chronic Spontaneous Urticaria
    Interventions:   Biological: Ligelizumab;   Biological: Omalizumab;   Other: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
    NCT03428646
    Condition:   Dermatitis, Atopic
    Intervention:   Drug: Dupilumab
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC